Table 1 Patient characteristics.

From: Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma

ALK + NSCLC patients analysed in this study (n = 38)

Age, median (range)

59 (39–80)

Sex, % male

53%

Smoking status (% never smokers)

79%

ECOG PS (%) at baseline

0

26

 

1

14

 

2

1

 

No data

2

Histology

Adenocarcinomaa

37/38

ALK fusion variantb

EML4-ALK V3

11

 

EML4-ALK V1/V2

22

 

Other

4

 

No data

1

TP53 status at baseline, mutatedc

9/36

ALK TKI, patient number

Crizotinib

23

 

Ceritinib/alectinib/brigatinib

32

 

Lorlatinib

4

Chemotherapy

7

Follow-up in months (median [Q1-Q3])

38 (26–52)

Number of samples analysed per patient (median [range])

8 (3–24)

Number of TKI lines covered with LiBx per patient, mean

2.1

Number of samples at disease progression with therapy change per patient, mean

0.95

  1. EML4-ALK echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion, PS performance status, TKI tyrosine kinase inhibitor, Q1 quartile 1, Q3 quartile 3, LiBx liquid biopsy.
  2. aOne patient had an ALK+ large-cell neuroendocrine lung carcinoma responsive to ALK inhibitors.
  3. bData available for 37/38 cases; one case with E18A20, one with E9A20, one with K9A20 (KLC1), and one with K24A20 (KIF5B).
  4. cData available for 36 cases by NGS of tissue biopsies at diagnosis of Stage IV disease.
Back to article page